Perhaps most impressive is BPC-157 activity against MPTP, a neurotoxin that selectively destroys dopaminergic neurons and is used to model Parkinson disease in research
BPC-157 (Body Protection Compound-157) is a synthetic peptide comprising 15 amino acids, thus making it a pentadecapeptide
A 10 mg vial with 2 mL yields 5 mg/mL
Jessen F, Amariglio RE, Buckley RF, et al
P140/Lupuzor reached Phase III clinical trials specifically for SLE, demonstrating that peptide-based approaches are being seriously investigated as therapeutic options
Impacts range from enhanced bleeding potential with blood thinners, disrupted glucose management with diabetes medications, and intensified hormonal responses to fertility drugs